| Myelodysplastic Syndromes Treatment (PDQ®): Health Professional Version |
|
PDQ Cancer Information Summaries |
Myelodysplastic Syndromes (MDS) |
| Heterogeneity in Health-Related Quality of Life of Patients with Aplastic Anemia: A Latent Profile Analysis |
|
Patient Preference and Adherence |
Aplastic Anemia |
| Experience of life quality from patients with aplastic anemia: a descriptive qualitative study |
|
Orphanet Journal of Rare Diseases |
Aplastic Anemia |
| Real-World Study of the Burden of Myelodysplastic Syndromes in Patients and Their Caregivers in Europe and the United States |
|
Oncology and Therapy |
Myelodysplastic Syndromes (MDS) |
| Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes |
|
Oncologist |
Myelodysplastic Syndromes (MDS) |
| STAT signaling in the pathogenesis and therapy of acute myeloid leukemia and myelodysplastic syndromes |
|
Neoplasia |
Myelodysplastic Syndromes (MDS) |
| Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes |
|
Nature Medicine |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
|
National Cancer Institute |
Myelodysplastic Syndromes (MDS) |
| TERC haploid cell reprogramming: a novel therapeutic strategy for aplastic anemia |
|
Molecular Medicine |
Aplastic Anemia |
| Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy |
|
Mediterranean Journal of Hematology and Infectious Diseases |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
